ERYTECH announces positive safety review for eryaspase in its Phase 2 study in pancreatic cancer Post author:admERY Post published:July 20, 2015 Post category:Newsroom ERYTECH announces a positive DSMB safety review following the treatment of the first twenty-four patients with eryaspase in its Phase 2 study in pancreatic cancer. You Might Also Like ERYTECH to Present at Cowen & Company 39th Annual Healthcare Conference Meeting March 8, 2019 ERYTECH Pharma to present promising results for the treatment of Sickle Cell Disease March 14, 2011 ERYTECH to Present at JMP Securities Life Science Conference June 20, 2018